to Content
Header Image

Epidemics – Pandemics

-
Erwin-Schrödinger-Saal
Plenary / Panel
German and English language
Vice President Research and Development, Baxter Vaccine AG, Orth an der Donau
Executive Vice President of Research & Development, Gilead Sciences, Inc., Foster City
Director, Max Planck Institute for Dynamics and Self-Organization, Göttingen; Professor of Theoretical Physics, University of Göttingen
Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, New York
Special Advisor on Influenza Pandemic Vaccine Development, WHO, Initiative for Vaccine Research, Department for Immunization, Vaccines and Biologicals, Geneva
Geschäftsführer, Ze.Wa. medicalsystems GmbH, Wien Chair

Dr. Noel BARRETT

Vice President Research and Development, Baxter Vaccine AG, Orth an der Donau

 Dr. Noel Barrett is Vice-President, Vaccines Research in the Bioscience Division of Baxter Healthcare. He received his B. Sc. in Microbiology at University College Cork, Ireland (1976) and his Ph. D. in Virology at Trinity College, Dublin (1979). He subsequently held a post-doctoral fellowship at the Dept. of Virology and Immunology, University of Würzburg, Germany for a period of four years. In 1983, he joined the Austrian company Immuno AG, which was subsequently acquired by Baxter Healthcare in 1997.
 Dr. Barrett has been responsible for a variety of functions in the Vaccine business unit including discovery research, clinical development, regulatory affairs and project management, in addition to being responsible for the pathogen safety program of the plasma division for a period of over ten years. He is currently a member of the Baxter AG, Austria board of directors, the Baxter International Senior Management Team and is site manager of the Biomedical Research Centre in Orth. Dr. Barrett has had over twenty years experience in the vaccine industry with management responsibilities covering the complete development process required to bring vaccine products to the market.

PhD Norbert W. BISCHOFBERGER

Executive Vice President of Research & Development, Gilead Sciences, Inc., Foster City

1984-1986 Postdoctoral Fellow, Harvard University, Cambridge, MA
1986-1990 Scientist, Genentech Inc.
1990-1997 Vice President of Research, Gilead
1997-2000 Vice President of Research & Development, Gilead
since 2000 Executive Vice President of Research & Development, Gilead Sciences, Inc.

Dr. Theo GEISEL

Director, Max Planck Institute for Dynamics and Self-Organization, Göttingen; Professor of Theoretical Physics, University of Göttingen

 Studies of Physics and Mathematics at the Universities of Frankfurt and Regensburg
1982 Habilitation Theoretical Physics, University of Regensburg
1988-1989 Professor of Theoretical Physics, University of Würzburg
1989-1996 Professor of Theoretical Physics, University of Frankfurt
since 1996 Professor of Theoretical Physics, University of Göttingen
since 1996 Director, Max Planck Institute for Dynamics and Self-Organization
 Director, Institute for Nonlinear Dynamics, University of Göttingen
 Head, Bernstein Center für Computational Neuroscience, Göttingen

Ph.D. Peter PALESE

Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, New York

 Ph.D Chemistry, University of Vienna
 Mag. pharm., University of Vienna
 Postdoctoral Fellow, Roche Institute of Molecular Biology, Nutley, New Jersey
 Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine

Dr. Klaus STÖHR

Special Advisor on Influenza Pandemic Vaccine Development, WHO, Initiative for Vaccine Research, Department for Immunization, Vaccines and Biologicals, Geneva

1987-1989 Scientist, Institute for Epidemiology and Communicable Disease Control, Federal Research Institute Wusterhausen/Tübingen
1989-1991 Head, Division of Infectious Diseases, Institute for Epidemiology and Communicable Disease Control, Federal Research Institute Wusterhausen/Tübingen
1992-1993 Associated Professional Officer (P2); WHO Division of Communicable Diseases, Veterinary Public Health Unit, Geneva
1994-1995 Scientist (P5); WHO Division of Communicable Diseases, Veterinary Public Health Unit
1995-1998 Scientist (P5); WHO Division for Emerging and other Communicable Diseases Surveillance and Control
1998-2001 Senior Scientist (P5); WHO Department of Communicable Diseases Surveillance and Response
2001-2004 Project Leader (P5); WHO Global Influenza Programme; WHO Department of Communicable Diseases Surveillance and Response
2003 Coordinator (P5); SARS Aetiology, Diagnosis and Treatment, WHO Department of Communicable Diseases Surveillance and Response
2004-2006 Coordinator (P5); WHO Global Influenza Programme WHO Department of Communicable Diseases Surveillance and Response
since 2006 Senior Advisor on Influenza Pandemic Vaccine Development, WHO Initiative for Vaccine Research, Department for Immunization, Vaccines and Biologicals

Dr. Hubert DRESSLER

Geschäftsführer, Ze.Wa. medicalsystems GmbH, Wien

1990-1991 Postgraduate Economics, European Business School, Eltville, Deutschland
1985-1986 Internship, Medical University of Otago, Dunedin, New Zealand
1986-1987 Internship, Children's Hospital Oakland, California, USA
1987-1990 Pharma-Produktmanager, Hoechst Austria AG
1990-1991 Produktmanager Herz-Kreislauf, Pharma Sales International, Hoechst AG, Frankfurt
1991-1992 Leiter Pharma, Nigerian Hoechst PLC
1992-1993 Stv. Geschäftsführer, Leiter Pharma, verantwortlich für Pharma-, Landwirtschafts- und Veterinärprodukte,
  Nigerian Hoechst PLC
1993-1994 Corporate Center, Projektarbeit Afrika, Hoechst AG, Frankfurt
1994-1995 Assistent von Dr. Seifert, Vorstandsmitglied der Hoechst AG, Frankfurt
1995-1998 Managing Director, verantwortlich für Pharma-, Diagnostika- und Veterinärprodukte in der Volksrepublik China,
  Hongkong und Taiwan, Hoechst Marion Roussel
1998-2000 Geschäftsführer, Österreich/Central Europe, Hoechst Marion Roussel
2000-2001 Geschäftsführer, Aventis Pharma GmbH
2001-2004 Head of Area, Austria & Switzerland, Aventis Pharma GmbH
2004-2008 General Manager, sanofi-aventis Österreich, Wien
2004-2010 Präsident, Verband der pharmazeutischen Industrie Österreichs, Wien
seit 2010 Geschäftsführer, Ze.Wa. medicalsystems GmbH, Wien

Health Symposium

show timetable